A leading boutique pharmacometrics consulting firm with expertise in building quantitative models to drive drug development.
We'd love to work with you!
Contact Us
Population PK Modeling
Identify influential covariates that can significantly impact drug exposure in patients
Exposure-Response PK/PD Modeling
Determine dose levels that can maximize efficacy and minimize adverse effect
Additional Services
NCA of PK and TK studies, PBPK modeling, trial design, preliminary analyses, and data management (CDISC, SDTM)
Experience
Led by Sam Liao, PhD, with over 35 years of experience, our small team of pharmacometricians and statisticians provides PK/PD model-based analyses and other consulting services to support pharmaceutical and biotech firms in clinical drug development.
- Population PK analysis
- Drug exposure-response PK/PD analysis of efficacy and safety data
- PK/PD analysis of categorical data, survival data, and ECG data
- Non-compartmental PK and TK analyses
- Phase I/II efficacy and safety analysis
- Design of phase II/III clinical studies using model-based strategies
- Dosage adjustment in special patient populations based on MC simulation
- Design and analysis of PK studies in pediatrics with limited samples
- IVIVC for sustained-release formulations